StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > US National TV - Sunday May 16

<< Previous

Bullboard Posts

Next >>

Comment by capebretongirlon May 10, 2021 11:54am

125 Views

Post# 33165165

RE:RE:RE:RE:RE:RE:RE: US National TV - Sunday May 16

The company is looking to the future as Tripp mentioned by expanding outside of cancer and the patent reflects this. We have no idea how close they are to perfecting testing for gastro, neuro and cardio, autoimmune etc. but we do know they are working on it. If we can just get Aristotle going, the Sentinel principle would be accepted for the rest. Hard to watch this struggling at .70.

davewho wrote:
The ARISTOTLE trademark was assigned a Serial Number #88292678 – by the United States Patent and Trademark Office (USPTO). Trademark Serial Number is a unique ID to identify the ARISTOTLE mark in USPTO. The ARISTOTLE mark is filed in the category of Pharmaceutical Products . The legal correspondent for ARISTOTLE trademark is Steven A. Abreu, Sunstein LLP, 100 High St. BOSTON MA 02110 . The current status of the ARISTOTLE filing is THIRD EXTENSION - GRANTED.

Based on StageZero Life Sciences Ltd., the ARISTOTLE trademark will be used in the following business: Medical diagnostic reagents and assays for testing blood for cancer; Medical diagnostic reagents and assays for testing blood for gastroenterology disorders, neurology disorders, cardiology disorders and autoimmune disorders; medical diagnostic test kits for Cancer screening .